Get started

Vaccine

SESN Sesen Bio Selloff | Buy the dip???SESN received a preapproval for the dug, Vicineum, but not in its present form. and the market overreacted to it. sold at market prices. and the price went down to 0.86usd, its strongest support. The FDA has determined that it cannot approve the BLA for Vicineum in its present form and has provided recommendations specific to additional clinical/statistical data and analyses in addition to Chemistry, Manufacturing and Controls (CMC) issues pertaining to a recent pre-approval inspection and product quality. (businesswire.com) And they don`t have only one product in their pipeline. Sesen Bio focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. (marketbeat.com) On 8/11/2021 BlackRock Inc. reported 10,657,812 for a total of $49.24M +264.7% increase and an ownership in SESN of 6.150% On 8/13/2021 Vanguard Group Inc. reported 8,503,982 for a total of $39.29M +18.2% increase and an ownership in SESN 4.339% My price target is between 2.7 to 3.2usd. I look forward to read your opinion
SLong
by TopgOptions
DYAI Covid-19 Vaccine for the African ContinentDyadic International signed a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium. The Rubic Consortium is made up of promoters of the project representing public health, medical, academia, vaccine technology, technology transfer and economics sectors. Arrangement includes C1 COVID-19 vaccine technology transfer and licensing agreement. Provides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through Phase II and Phase III clinical trials. Establishes co-development basis for researching, developing and manufacturing multiple other C1 produced vaccines in addition to DYAI-100. Intends to reduce African dependence on foreign vaccine suppliers. Combined with previous C1 COVID-19 vaccine collaborations in India and South Korea (including Southeast Asia), this agreement further supports the potential for C1 produced COVID-19 immunization coverage to more than 40% of the world’s population. (rubicconsortium.co.za) Now what is the potential for DYAI??? The 52 Week Range is 3.1500 - 9.1900 Now the price is 3.89usd, so close to the lower end. The market cap is only 107Mil The biggest owner, 4.744%, is BlackRock Inc. which reported on 5/7/2021 1,307,205 shares on DYAI for a market value of $7.18Mil. if we make an average, Blackrock bought DYAI at 5.5usd per share. and i don`t think it will sell for less, especially with new COVID-19 vaccine coming. The second important owner is Vanguard Group Inc., which has 709,698 shares at a market value of $4.44Mil. they bought DYAI at 6.25usd and didn`t panic sell when the stock went to 2.5usd! My short term price target is 6.5usd, but on the long run, depending on the efficacy of the vaccine, this company can worth Billions! Just remember MRNA before it made 25X!
NASDAQ:DYAILong
by TopgOptions
1
Testing kits on Delta VariantFundamental Quidel: a manufacturer of diagnostic products, frequently rises or sinks in response to developments in the coronavirus pandemic, as a big part of their revenue comes from its COVID-19 testing kits. As the Delta Variant is worrying countries around the globe, QDEL will be interesting to watch. Technical Analysis As you can see in the weekly chart, the blue horizontal line which is approximately $150 was tested multiple times, is now also coinciding with the 50ema, which has worked well as support. A potential target could be in place, as there is still a downtrend from the Pfizer Vaccine initial news of 95% efficacy.
NASDAQ:QDEL
by dorfmanmaster
1
NRBO 400% Upside Potential | Covid-19 TreatmentOn 4/20/2021 HC Wainwright brokerage Reiterated Rating to Buy and a Price Target of $16.00 for NRBO But how come? What`s the catalyst? Why NeuroBo Pharmaceuticals was up 40% yesterday? Richard J. Kang, CEO: "Throughout the first quarter of 2021, we continued to make progress advancing the 60-patient Phase 2/3 clinical trial of our lead drug candidate, ANA001, a proprietary oral niclosamide formulation, as a treatment for moderate to severe COVID-19." "we expect to report preclinical in vitro data demonstrating Gemcabene's ability to treat COVID-19 variants alone and in combination with ANA001." "NeuroBo has the financial foundation to fund operations at the current level into the fourth quarter of 2021 and we expect to achieve a number of value-creating milestones with our COVID-19 programs in the coming months." Besides the Covid-19 treatment, NeuroBo Pharmaceuticals has a current portfolio of four drug candidates focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. The Market Cap if only 88.473Mil at the time or writing!
NASDAQ:NRBOLong
by TopgOptions
4
In search for the next BNTX, MRNA and NVAX !!Since Covid-19 is here to stay with us with its variants and the vaccines don`t offer lifetime protection, this means that there is room for other companies to develop a better vaccine to address the problem. And the gains in vaccines stock are quite similar to cryptocurrencies year over year. From all time low to all time high, BNTX made 19X, MRNA 24X and NVAX 66X. My question for you is the following: which is the next vaccine developer to make at least 10X our money?? I`m looking forward to discover with you the next big vaccine developer! And i have a presumption or two which i already shared in my group. And those were the fundamentals i was searching for: data submitted to FDA for Emergency Use Authorization, Phase 3, low Market cap - under 1Bil, on the lower end of 52 Week Range, other drugs in the pipeline, high intraday volume.
NASDAQ:BNTXLong
by TopgOptions
18
NVAX Novavax Analyst RatingsOn 6/15/2021 Cantor Fitzgerald brokerage Boosted the Price Target from Reduce to Overweight $217.00 to $272.00 On 5/18/2021 JPMorgan Chase & Co. brokerage Reiterated Rating from Overweight to Neutral $285.00 to $161.00 On 5/12/2021 B. Riley brokerage Lowered the Price Target from $365.00 to $286.00 On 5/12/2021 HC Wainwright brokerage Lowered the Price Target from $317.00 to $294.00 My personal price target is $240. Looking forward to read your opinion.
NASDAQ:NVAXLong
by TopgOptions
Vaccine Counter PHARMA Downtrend SignsSupposedly the beneficiary of the vaccine story as one of the appointees approved by the government. A duopoly with DPHARMA. However... their price & volume action is dimming fast.. The cup and handle pattern is invalidated. The recent decision to prioritize Pfizer vaccine over Sinovac really trigger a sell-down on PHARMA stock price with high volume. Expect continued selling in the coming days. www.straitstimes.com The rest of the vaccine related stock hype: Kanger, Solution, HWGB, Yongtai, Bintai , yet to see any new development as the government controlled tightly the distribution and sale of vaccine to the public from third parties. Disclaimer This information only serves as reference information and does not constitute a buy or sell call. Conduct your own research and assessment before deciding to buy or sell any stock
MYX:PHARMAShort
by Gilazilla
Trading Idea - #CUREVAC (hope for the mutants)THE BIG LONG! Vaccine for the Covid-Mutants! :-) ENTRY: 44.20 EUR TARGET: 90.00 EUR (104 % profit) STOP: 32.40 EUR - This is only an interim analysis result of the CUREVAC Covid vaccince!! - Initial analyzes have shown that the effectiveness depends on the age group examined and the virus strains, the company continues. - The vaccine candidate is in the final stage of clinical development. - CEO Franz-Werner Haas announced that one had hoped for stronger results in the interim analysis. - But continue the current study until the final analysis.
XETR:5CVLong
by Traderherz-Analytics